According to the Revised Fourth Edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, at least 50% and 40% of neoplastic cells should express BCL2 and MYC, respectively, in order to consider a DLBCL-NOS patient as a DE [1]. Here, BCL2 is linked to neoplasm.